KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

Jadoul, Michel; Awan, Ahmad; Berenguer, Marina; Bruchfeld, Annette; Fabrizi, F.; Goldberg, David S.; Jia, Ji-dong; Kamar, Nassim; Mohamed, Rosmawati; Pol, Stanislas; Sise, Meghan E.; Martin, Paul

doi:10.1016/j.kint.2022.07.013

Cited by 21 publications

(25 citation statements)

References 361 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our review has enabled updated guidance from KDIGO regarding appropriate management of CKD patients with HCV infection. 2 Based on the strength of evidence for each DAA regimen, the 2022 KDIGO guidelines provide recommended treatments for each CKD stage.…”

Section: Discussionmentioning

confidence: 99%

“…We conducted this systematic review based on standard KDIGO and Agency for Healthcare Research and Quality methods, 2 , 12 in accordance with the Preferred Items for Reporting in Systematic Reviews and Meta-Analyses. 13 …”

Section: Methodsmentioning

confidence: 99%

“…Since the 2018 update of the KDIGO guideline on the management of HCV in CKD, 1 there has been a large volume of new evidence to support use of DAA regimens for patients with CKD. To enable the 2022 KDIGO update 2 and its determinations of recommended regimens, a systematic review of each regimen’s effectiveness and safety was needed.…”

mentioning

confidence: 99%

“…To support the 2022 update of the KDIGO guideline on the management of HCV in CKD, 2 we conducted a systematic review with meta-analysis of benefit and safety outcomes of all available DAA regimens specifically in patients with CKD G4–G5ND, on dialysis, and among KTRs.…”

mentioning

confidence: 99%

See 3 more Smart Citations

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

Balk¹,

Adam²,

Jadoul³

et al. 2023

Kidney International Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

Balk¹,

Adam²,

Jadoul³

et al. 2023

Kidney International Reports

View full text Add to dashboard Cite

“…Additionally, CHC in HD-dependent patients negatively affects overall survival and results in an increased risk of cirrhosis, HCC, and a lower quality of life compared to their HCV-negative counterparts [ 6 , 8 , 9 ]. Therefore, all patients with end-stage renal disease (ESRD) should be considered for AVT [ 1 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Are We on the Right Track for HCV Micro-Elimination? HCV Management Practices in Dialysis Centers in Poland—A National Cross-Sectional Survey

Czarnecka

Tronina

et al. 2023

JCM

View full text Add to dashboard Cite

Chronic hepatitis C (CHC) is prevalent in the hemodialysis-dependent population. Currently, all patients with CHC should be considered for treatment; however, many hemodialysis-dependent patients are still left untreated. Following HCV cure, accurate surveillance is mandatory to reduce liver-related mortality and prevent reinfection. We aimed to establish HCV management practices and barriers to HCV elimination in dialysis centers in Poland. Polish dialysis centers were surveyed via email. The HCV management strategies were investigated. Representatives of 112 dialysis centers responded, representing 43.1% of all dialysis centers in Poland and 43.4% of hemodialysis-dependent patients’ volume. Most respondents were Heads of hemodialysis centers and board-certified nephrologists. The study demonstrated that in the vast majority of hemodialysis centers (91.6%), subjects are considered for antiviral treatment (AVT); however, many obstacles preventing patients from being prescribed AVT were identified; patients’ reluctance to undergo AVT was most reported (60%). The majority of dialysis units neither evaluate patients with CHC for liver fibrosis (60.4%) nor screen them for hepatocellular carcinoma (53.5%). In conclusion, the presented study demonstrates that HCV management practices across Polish dialysis centers vary substantially. There is a need to optimize and streamline the HCV management infrastructure in the hemodialysis population in Poland.

show abstract